Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

World AMR Awareness Week Resources

Menarini is committed to developing effective solutions to address the global threat of antibiotic antimicrobial resistance. We work together with a range of stakeholders to achieve this. On this page you will find several resources that Menarini helped develop to improve AMR awareness and management.

Academic posterand publication

Menarini supported a narrative review showcasing the impact of AMR on patients with cancer and organ transplant recipients. The data were presented in a poster at the Basel AMR Conference in February 2025 and fully published in Infectious Diseases and Therapy in August 2025. Due to their weakened immune systems, antibiotics play a key role in treatment for cancer and transplant recipients and consequently antimicrobial resistance is especially dangerous for them.

The publication concludes with a call to action to recognise the threat of AMR and ensure novel antibiotics have commercial viability and that surveillance and stewardship programmes are implemented. 

Infection in focus

I AM AMR

AMR is a threat to the whole healthcare system as we know it. Keeping AMR under control will require the cooperation of all stakeholders - clinical experts, patient representatives, NGOs and many more. Menarini brings together leading experts in this I AM AMR video campaign, highlighting the concerns these actors have regarding AMR and affirming that I AM AMR means that AMR is an issue that affects all of us.

Patient testimonial Vanessa Carter (The AMR Narrative)

Patients are at the heart of our healthcare system. Understanding their lived experiences is key to help improve it. Vanessa Carter, founder and executive director of The AMR Narrative, shares her experience. Vanessa has been an AMR patient advocate since 2013 and has served on the WHO Strategic Technical Advisory Group on AMR (2020-2023).

Guardian-Mediaplanet awareness campaign

In support of World Antimicrobial Awareness Week, the Guardian and Mediaplanet aim to raise awareness for the key challenges in the fight against AMR and the need for cross-sector collaboration and investment on a global scale. The campaign will call for action from the general public, healthcare professionals, industry, government and NGOs to help slow the acceleration of AMR. Menarini will participate along with other key stakeholders like World Health Organisation, IFPMA, GARDP, AMR Industry Alliance, AMR Action Fund and ESCMID.

Menarini at the World Sepsis Congress Satellite Session on AMR, Sepsis and Cancer

Sepsis and AMR represent two of the most critical public health challenges of our time. Infections that lead to sepsis are often caused by drug-resistant organisms, making patient treatment immensely difficult and contributing to higher mortality rates.

Menarini is proud to join the Global Sepsis Alliance at the World Sepsis Congress Satellite Session on AMR, Sepsis and Cancer to discuss how these issues are interlinked and what to do to turn the tide.